Advanced Search

Submit Online

Application Note

< Previous         Next >  
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
Kei Miyakawa1 , Sundararaj Stanleyraj Jeremiah1 , Hideaki Kato2 , Yutaro Yamaoka1,3 , Hirofumi Go4 , Satoshi Yajima5 , Tomoko Shimada6 , Takahiro Mihara7 , Atsushi Goto7 , Takeharu Yamanaka4,7 , Akihide Ryo1,*
1Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
2Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan
3Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Japan
4Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
5Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
6Nursing Department, Yokohama City University Hospital, Yokohama, Japan
7Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
*Correspondence to:Akihide Ryo , Email:aryo@yokohama-cu.ac.jp
J Mol Cell Biol, Volume 13, Issue 12, December 2021, 918-920,  https://doi.org/10.1093/jmcb/mjab050

The uncontrolled spread of the coronavirus disease 2019 (COVID-19) pandemic has led to the emergence of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut is threatened by the rapidly spreading variants of concern (VOC) and other regional mutants, which are less responsive to neutralization by infection- or vaccine-derived antibodies (Gomez et al., 2021; Wang et al., 2021).


Volume 13, Issue 12
December 2021